Pilot study for optimising paediatric brain tumour therapy
New therapies are critically needed for paediatric brain tumours, the main cause of cancer-related death in children and adolescents. Conventional chemotherapy and radiotherapy are often not effective and curative options are limited for many patients.
Aim of the trial
Ana Guerreiro Stücklin, neuro-oncologist and senior physician at the University Children’s Hospital Zurich, and her team are developing an innovative precision medicine platform for therapy optimisation for children with brain tumours, focusing on those with tumours refractory or resistant to standard therapies. Building a comprehensive rapid drug testing pipeline, they assess each tumour’s response to new anti-cancer agents, enabling personalised and novel treatment options for patients.
The successful implementation of this paediatric brain tumour therapy optimisation pipeline has the potential to transform treatment and improve the survival chances of children and adolescents with brain tumours.
University Children’s Hospital Zurich